What is Parallel Bio?
Parallel Bio is a Cambridge-based biotechnology firm that is redefining the drug discovery pipeline through the integration of organoids and advanced machine learning. By creating scalable, true-to-life models of the human immune system, the company enables researchers to predict drug success with unprecedented precision. This approach effectively mitigates the risks associated with traditional preclinical trials, which often fail to capture the complexities of human biological diversity. With a focus on immunotherapies, the company provides a robust, data-rich environment for pharmaceutical development, effectively bridging the gap between laboratory research and clinical application.
How much funding has Parallel Bio raised?
Parallel Bio has raised a total of $25.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$21M
Angel/Seed (2022): $4.3M with participation from Y Combinator, Breakout Ventures, and Refactor Capital
Series A (2025): $21M led by Metaplanet, Atypical Ventures, AIX Ventures, Undeterred Capital, and Amplo
Key Investors in Parallel Bio
Metaplanet
Metaplanet is an early-stage investment firm that focuses on backing mission-driven founders working on positively disruptive deep technologies, prioritizing long-term investments in tech that supports humanity's survival.
AIX Ventures
AIX Ventures is a venture capital firm focused on investing in seed stage AI startups and partnering with top AI practitioners to transform industries.
Breakout Ventures
Breakout Ventures is a venture capital firm focused on investing in transformative companies that leverage scientific innovation and technology to create new markets.
What's next for Parallel Bio?
With this major enterprise-level funding, Parallel Bio is poised to expand its operational capacity and deepen its partnerships with global pharmaceutical entities. The strategic roadmap likely includes scaling the production of its immune organoids and enhancing the predictive capabilities of its AI models to cover a broader spectrum of disease targets. As the company matures, the focus will shift toward commercializing its platform as a standard-bearer for safety and efficacy testing, potentially disrupting the conventional drug development lifecycle. Investors are closely watching how the firm leverages this capital to solidify its market position and accelerate the delivery of next-generation therapeutics to the clinical stage.
See full Parallel Bio company page
